Skip to content
IP + Technology Law
Home  »  News & Insights  »  News

Partner Michael Fuller comments in Law 360 article, “More PTAB Fights Between Big Pharma Could Be Looming.”

July 19, 2017  | Michael L. Fuller

Partner Michael Fuller was quoted in, “More PTAB Fights Between Big Pharma Could Be Looming,” an article published in Law360.

Excerpt: Pharmaceutical firms like Pfizer Inc. are accustomed to having their patents for brand-name drugs challenged by generics makers at the Patent Trial and Appeal Board.

Read Full Article Here >> (subscription required)

Partner Michael Fuller comments in Law 360 article, “More PTAB Fights Between Big Pharma Could Be Looming.” Headshot

Michael L. Fuller

Mike Fuller is a technology enthusiast and widely regarded for his expertise in obtaining, licensing, and managing due diligence on patents involving molecular biology and computer science. Mike is a...

Related Links

Industries

News & Insights

Blog - IP Practice
Mar 2025
Inaction Can Lead To Argument Forfeiture on Appeal
ALIVECOR, INC. v. APPLE INC. Before Hughes, Linn, and Stark. Appeal from Patent Trial and Appeal Board Summary:  A party in a PTAB proceeding forfeits the ability to challenge an...
Blog - IP Practice
Mar 2025
Limits of Inherent Anticipation in Product-By-Process Claims
RESTEM, LLC v. JADI CELL, LLC Before Moore, Schall, and Taranto. Appeal from the Patent Trial and Appeal Board. Summary: Inherency in product-by-process claims requires the prior art process to...
Blog - IP Practice
Mar 2025
Jepson Claim Preamble Requires Written Description Support for Conventional Aspects of the Invention
IN RE: XENCOR, INC. Before Hughes, Stark, and Schroeder (sitting by designation).  Appeal from the U.S. Patent and Trademark Office, Patent Trial and Appeal Board. Summary: To provide adequate written...